SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...
WASHINGTON, DC—An exploratory analysis of the PROTECTED TAVR trial suggests that use of the Sentinel cerebral embolic protection system (Boston Scientific) during TAVI had a greater impact in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback